论文部分内容阅读
心血管疾病居我国人口死因之首位,高脂血症是导致心脑血管疾病、冠心病和脂肪肝等一系列疾病发生的危险因素。因此,采取积极有效的药物干预,防治高脂血症成为目前我国临床界迫在眉睫的任务。 中国中医研究院老年病研究所周文泉研究员等人从1983年开始,针对老年脂血症本虚标实的病机,对不同证型的老年高脂血症患者采用辨证论治——分型定方——系列治疗的方法,历经10年的探索和研究.终于研制出三种防治高脂血症新药——滋肾通脉胶囊、滋肾胶囊和通脉胶囊。该项成果已于1994年12月13日通过以董建华等专家组成的专家鉴定委员会鉴定。
Cardiovascular disease ranks first in the cause of death in China. Hyperlipidemia is a risk factor for the occurrence of a series of diseases such as cardiovascular and cerebrovascular diseases, coronary heart disease and fatty liver. Therefore, taking active and effective drug intervention to prevent and treat hyperlipidemia has become an urgent task for the clinical community in China. Researcher Zhou Wenquan from the Institute of Geriatrics of the Chinese Academy of Traditional Chinese Medicine and others began in 1983 to address the pathogenesis of senile dyslipidemia and to use syndrome differentiation and treatment for different syndromes of elderly hyperlipidemia patients. ——A series of treatment methods, after 10 years of exploration and research, finally developed three new drugs to prevent hyperlipidemia - Zishen Tongmai Capsule, Zishen Capsule and Tongmai Capsule. This achievement was approved by the expert appraisal committee composed of experts such as Tung Chee Hwa on December 13, 1994.